Donald Huddler, GSK, to present on fragment screening at Assay meeting, Oct. 24th-26th, Philadelphia
Donald Huddler, Investigator of Biophysics Group - Computational and Structural Chemistry at GlaxoSmithKline will give a presentation on 'Fragment Screening Strategies for Difficult or Unprecedented Targets - Leveraging SPR and NMR' at GTC's 7th Assay & Drug Discovery Technologies conference (October 24th-26th, 2012 in Philadelphia, PA).
- (1888PressRelease) September 20, 2012 - An increasing percentage of the contemporary drug discovery targets are novel or with limited precedence. The majority of these novel targets have little or no chemical matter in the literature. For the small percentage of truly novel targets that do have published chemical matter, many, upon careful examination, are revealed to be nuisance mechanism compounds of no utility. Consequently, the biophysics team is left with a challenging, novel target, with no validated compounds to develop and optimize direct binding screening assays. In Dr. Huddler's group, they have employed a general approach relying on saturation transfer difference (STD) NMR and SPR as well as a small, highly soluble, fragment library to quickly identify and validate reversibly binding compounds. Systematic application of this biophysics approach has yielded novel fragments for an array of non-traditional discovery targets.
Donald Huddler, Ph.D., is an Investigator and biophysics team leader at GlaxoSmithKline, plc in the Computational and Structural Chemistry Department (Collegeville, PA, USA). His group integrates SPR, NMR, and other biophysical methods to support Fragment-Based Lead Discovery efforts. Prior to GSK, Donald was a group leader at the Walter Reed Army Institute of Research, focused on applying structure-based drug design methods to neglected diseases and diseases common in the Developing World.
This 7th Assay & Drug Discovery Technologies Conference is part of a larger summit. Other tracks for this summit include:
8th Modern Drug Discovery & Development Summit
(Day 1, Oct 24, 2012) - Plenary Keynote Session
(Day 2-3, Oct 25-26, 2012) - Breakout Tracks:
9th Stem Cell Research & Therapeutics
3rd Pharmacokinetics & Pharmacodynamics
4th Translational Medicine
Biotechnology Transfer & Commercialization
For more information, please visit www.gtcbio.com/assay
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam